MAX vs NBIX · P/E 36, rev $864.7M vs P/E 45, rev $2.36B
MediaAlpha Inc. (MAX) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
MediaAlpha Inc. (MAX) is a internet content & information company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported MAX revenue for 2024-12-31 was $864.7M. Net income was $22.1M. Revenue was up 122.8% from 2023-12-31 to 2024-12-31. MAX currently screens at market cap $689.0M and trailing P/E 36.2.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
MAX currently screens at market cap $689.0M and trailing P/E 36.2. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the MAX and NBIX stock pages for the full models.
Not investment advice.